UNSPSC 51381802: Oxepinac

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H12O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PF3750D8AE, chemically known as 6,11-dihydro-11-oxodibenz(b,e)oxepin-3-acetic acid but generally known as oxepinac, which bears US NIH Compound Identifier 41531. European Medicines Agency schedules Oxepinac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09515MIG. The term OXEPINAC is an International Non-Proprietary Name.

UNSPSC 51381802 Oxepinac is a Commodity code that in recent state and local practice covers procurement of pharmaceutical products and related health supplies, though the code's nominal focus on a single active pharmaceutical ingredient diverges notably from the actual scope of recent solicitations. State and local governments are buying broad categories of pharmaceuticals—generic multi-source drugs, over-the-counter products, naloxone (an opioid antagonist), and drug deactivation systems—through health departments, cooperative purchasing alliances, and community health initiatives. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing organizations. The procurement vehicles range from traditional IFBs for specific product quantities to RFIs for capability assessment and RFPs for manufacturer contracts spanning multiple jurisdictions and authorized distribution channels.

Recent activity shows geographic spread across Florida, Texas, and Minnesota, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issuing a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local government facilities, including Oregon. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026 (due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with vendors required to include shipping and delivery costs in proposals and maintain commercial general liability and workers' compensation insurance. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 to gather vendor capabilities regarding direct-to-manufacturer prescription programs for its Therapeutic Pharmacy Initiative, seeking vendor experience with self-insured employer and state agency contracting outside traditional pharmacy benefit manager arrangements. The MMCAP procurement requires cGMP certification, Drug Supply Chain Security Act compliance, and contractual relationships with at least two of three authorized wholesalers; contract term is two years with optional extensions, and pricing evaluation weights price competitiveness at 75 percent.